2Firsts Convenes 2025 Insight Forum on Dual Challenges of U.S. NGP Regulation & Tariff Trends/ Closed-Door Forum on Nicotine Pouch PMTA Technical Analysis

May.16.2025
2Firsts Convenes 2025 Insight Forum on Dual Challenges of U.S. NGP Regulation & Tariff Trends/ Closed-Door Forum on Nicotine Pouch PMTA Technical Analysis
2Firsts hosted a seminar in Shenzhen on 2025 Insight Forum on Dual Challenges of U.S. NGP Regulation & Tariff Trends/ Closed-Door Forum on Nicotine Pouch PMTA Technical Analysis. Experts from CSUR provided in-depth analysis of compliance pathways, aiming to help the industry navigate dual challenges of regulation and tariffs.

【2Firsts-Shenzhen】On the afternoon of April 16, the leading global aerosol technology media and think tank 2Firsts successfully held a closed-door seminar in Shenzhen Qianhai, titled "2025 Insight Forum on Dual Challenges of U.S. NGP Regulation & Tariff Trends/ Closed-Door Forum on Nicotine Pouch PMTA Technical Analysis".

 

The forum was divided into two sessions, with the first session focusing on the technical analysis of nicotine pouches' PMTA, delving into the compliance pathway of nicotine pouches in the US market. The second session revolved around the interpretation of the trends of new tobacco regulations and dual tariff challenges in the United States in 2025, providing attendees with insights into the future regulatory and tariff policies of the US. The conference attracted representatives of dozens of nicotine pouch and e-cigarette companies in terms of technology and compliance, collectively discussing key industry development issues and providing valuable insights and strategies for addressing future challenges.

 

Dr. Andrea Patton, the head of epidemiological research at the Centre for Substance Use Research (CSUR), along with co-director Gabriel Barnard, were invited to attend this seminar and each gave a keynote speech.

 

Dr. Andrea Patton gave a speech titled "Use of Zyn Nicotine Pouches in the United States: Quantifying Population-Level Risk and Benefit in a PMTA Framework.

 

美国CSUR受邀参加2FIRSTS尼古丁袋PMTA技术分析暨美国监管动向研讨会并发表主题演讲
Dr. Andrea Patton delivering a video speech | Image source: 2Firsts

 

Using ZYN's PMTA (Premarket Tobacco Product Application) approval as a case study, she systematically introduced the public health standards that new tobacco products need to meet in order to be approved for market in the United States. She analyzed the key types of research involved in the PMTA framework, and detailed how to scientifically quantify the risks and benefits at the population and non-population levels.

 

Dr. Patton pointed out that the approval of ZYN provides a "reference benchmark" for future applicants to evaluate the "level of acceptable use" of products among different populations, demonstrating significant industry implications.

 

Gabriel Barnard gave a keynote speech titled "A Perception and Behavioral Strategy to Quantify the Public Health Impact of an Oral Nicotine Pouch Product in the United States".

 

2Firsts Convenes 2025 Insight Forum on Dual Challenges of U.S. NGP Regulation & Tariff Trends/ Closed-Door Forum on Nicotine Pouch PMTA Technical Analysis
Video footage of Gabriel Barnard's speech on stage | Image source: 2Firsts

 

During the speech, Gabriel Barnard provided a detailed analysis of the Pre-Market Tobacco Product Application (PMTA) review framework, outlining the specific types of research and key information requirements that nicotine pouch manufacturers need to focus on during the application process. He presented three recommended research directions to help applicants meet the public health assessment standards of PMTA.

 

·Actual Use Study

·Behavior Intent ions and Risk Perceptions Study

·Label Comprehension and Usability Study

 

Subsequently, Gabriel Barnard systematically explained the important role of these three types of research in PMTA applications from the dimensions of regulatory compliance and scientific basis, providing practical strategic guidance for the registration path of nicotine pouch products.

 

Dr. Andrea Patton and Gabriel Barnard's professional presentations were widely praised and enthusiastically received by attendees. Many delegates expressed that the insights and compliance guidance shared by the two experts provided them with valuable industry knowledge, helping them to gain a deeper understanding of key assessment criteria for PMTA applications, methods for quantifying product benefits and risks, and the application of multidisciplinary research in compliance processes.

 

At the same time, attendees also expressed sincere gratitude to the two organizers, believing that this forum has built a high-quality compliance communication platform, greatly promoting communication and collaboration among various industry participants, and playing a positive role in pushing the new tobacco industry to take solid steps on the path of compliant development.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Nature Health Comment Urges Wider Role for Smoke-Free Nicotine Products in Tobacco Control
Nature Health Comment Urges Wider Role for Smoke-Free Nicotine Products in Tobacco Control
Ahead of World No Tobacco Day, a Nature Health Comment by Robert Beaglehole, Ruth Bonita and Tikki Pang argues that regulated smoke-free nicotine products could help accelerate the global decline in smoking. The authors propose a “smoke-free 2040” goal and call for risk-proportionate regulation distinguishing cigarettes from lower-risk nicotine alternatives.
News
May.20
China Tobacco Hubei Industrial Patent Discloses Nicotine Tooth Patch for Fixed Oral Delivery
China Tobacco Hubei Industrial Patent Discloses Nicotine Tooth Patch for Fixed Oral Delivery
According to Chinese patent records, a “nicotine tooth patch” application filed by China Tobacco Hubei Industrial Corporation (CTHB) and Hubei Xinye Tobacco Sheet Development Co., Ltd. was published on May 19, 2026. The filing proposes a nicotine gel patch that adheres to the tooth surface, especially the lingual side, to reduce displacement, foreign-body sensation, and accidental swallowing risks associated with existing oral nicotine products.
Jun.10
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands Pulls myblu Vape Business From U.S., Citing Prolonged FDA Approval Process
Imperial Brands said it will phase out its myblu vaping business in the United States, citing prolonged FDA approval timelines for new vape products. The company said it will instead focus on modern oral nicotine products in the U.S., including the expansion of its Zone brand and new flavors. While overall next-generation product revenue continued to grow, revenue from the category in the Americas declined sharply.
May.12
Philip Morris Says Its Smoke-Free Transition in Spain Now Has Economic Impact Above EUR 3.3 Billion
Philip Morris Says Its Smoke-Free Transition in Spain Now Has Economic Impact Above EUR 3.3 Billion
Philip Morris said it is accelerating its transition toward smoke-free products in Spain and claimed that the related economic impact now exceeds EUR 3.3 billion. Philip Morris also said that more than 90% of nicotine consumption in Spain still comes from conventional cigarettes, leaving room for growth in smoke-free categories, while regulation and taxation remain major obstacles in its view.
Apr.21 by 2FIRSTS.ai
 RFK Jr. Spokesman Resigns Over FDA Authorization of Fruit-Flavored Vapes
RFK Jr. Spokesman Resigns Over FDA Authorization of Fruit-Flavored Vapes
Richard Danker, a senior public affairs official in Health Secretary Robert F. Kennedy Jr.’s team, resigned from his role at HHS over the FDA’s recent authorization of fruit-flavored vaping products. In a resignation letter addressed to President Donald Trump, Danker argued that the products could expose minors to nicotine addiction, lung damage, and increased cancer risks, while also conflicting with recent HHS guidance on youth risks associated with flavored nicotine products.
News
May.15
PMI’s Smoke-Free Business Accounts for 43% of Net Revenues in Q1 as Full-Year EPS Guidance Rises
PMI’s Smoke-Free Business Accounts for 43% of Net Revenues in Q1 as Full-Year EPS Guidance Rises
On April 22, 2026, Philip Morris International released its first-quarter 2026 results. The report showed net revenues of $10.146 billion, up 9.1% year on year; adjusted diluted EPS of $1.96, up 16.0%; and smoke-free products accounting for 43% of total net revenues. Based on first-quarter performance, the company raised its 2026 full-year adjusted diluted EPS forecast to $8.36 to $8.51, or $8.11 to $8.26 excluding currency.
Apr.23 by 2FIRSTS.ai